therapies targeting DNA repair pathways in prostate cancer, patients with BRCA1 and BRCA2 mutations, failure of PARP inhibitors leading to psa reductions, how ATM differs from BRCA1 and BRCA2, atm’s function, treatment solutions for patients with ATM mutations outside of PARP inhibition, dna damage sensors
Patient-Specific 3D-VR Anatomical Modeling, DICOM Images, Patient-Specific 3D-VR Anatomical Modeling for Presurgical Planning Using DICOM Images and Open-Source Software, PSMA PET/CT, 99mTc-PSMA-I&S, salvage pelvic lymph…
Zachary Klaassen speaks with Pedro Barata about chemohormonal therapy and treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Barata traces the evolution from 2015 when…
At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman presents the PRIMARY score for PSMA PET in prostate cancer diagnosis. He explains how PSMA PET complements…
Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann…
At the 2025 UCSF-UCLA PSMA Conference, Wayne Brisbane presents a phase I trial examining PSMA-targeted prostate biopsy following negative/discordant MRI biopsies. Among 39 patients with…
Zachary Klaassen interviews Neal Shore about real-world treatment patterns for mCRPC patients in community urology centers using the PRECISION database. Dr. Shore analyzes data from…
Ashish Kamat speaks with Marco Moschini about expanding active surveillance criteria for recurrent low-grade bladder cancer. Dr. Moschini presents his single-center retrospective study from San…
erectile dysfunction, inflatable penile prosthesis (IPP), Satisfaction Survey for Inflatable Penile Implant (SSIPI), better patient care for Spanish speaking individuals undergoing inflatable penile prosthesis surgery.
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alicia…
At the 2025 UCSF-UCLA PSMA Conference, Amir Iravani compares FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. Dr. Iravani notes similar…
